The disappointing data Pfizer announced on its obesity pill are opening up opportunities for biotechs developing their own oral weight-loss drugs. Drugmakers are increasingly focused on the ...

Pfizer hopes to benefit from that hype as it works feverishly on a weight loss pill it believes could be one of the first to ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...

Pfizer has yet to distinguish itself in the increasingly competitive race for weight-loss primacy, and is continuing to work on a weight-loss pill. Bourla said in the May interview that the ...

Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...

Paxlovid, its antiviral pill, brought in $2.7 billion in sales ... FTC sues drug middlemen for allegedly inflating insulin ...

Novo Nordisk and Eli Lilly are also working on developing their own next-gen weight loss drugs. Pfizer seems to be primarily focused on incretin pills. Weight loss medications that already on the ...

Meanwhile, its weight-loss pill, danuglipron, stumbled in early trials — raising questions of whether Pfizer will get any piece of the weight-loss market pie before robust competition builds up.